- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02051634
Papaya Study ID:20140628
Efficacy of Fermented Papaya Preparation on Markers of Systemic Inflammation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All of the participants in this research study will be divided randomly into one of two groups: (1) a group taking fermented papaya preparation (FPP) for 8 weeks then taking placebo for 8 weeks or (2) a group taking placebo for 8 weeks then taking FPP for 8 weeks. Placebo sachets do not contain any treatment product. Participants will be assigned randomly to be in one of these two groups.
Participants will be asked to take study product for 8 weeks each, and participation in the study will last for a total of approximately 22 weeks. Participants will be asked to attend five study visits at the University of Florida's Institute on Aging - Clinical & Translational Research Building (IOA - CTRB): Screening Visit, Visit 1, Visit 2, Visit 3, and Visit 4. Visit 1 will take place approximately 30 days after the Screening Visit. Visit 2 will take place approximately 8 weeks after the Screening Visit. Visit 3 will take place approximately 16 weeks after the Screening Visit. Visit 4 will take place approximately 20 weeks after the Screening Visit. Participants will be asked to fast (i.e., no food or liquids except water) for 8 hours prior to all clinic visits. Each visit will take approximately 1.5 to 2 hours.
Participants will also be called weekly during the study to ask how they are feel and to find out and if they remembered to take all of their study product. Finally, investigators will call approximately two weeks after participants stop taking the study product to ask how they are feeling.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index > 25 and < 40 kg/m2;
- Willing and able to participate in all aspects of the study;
- Self-reported sedentary to moderately active lifestyle (<120 min aerobic activity/week);
- Self-reported ability to walk ¼ mile without the use of an assistive device (i.e., cane, walker, crutch);
- Mild to Moderate physical impairment (SPPB score 4-10);
- Not confined to a wheelchair;
- Mini Mental Status Exam score > 24;
- Able to swallow study product as directed.
Exclusion Criteria:
- Failure to give consent;
- Active treatment for cancer (< 3 years);
- Stroke (< 6 mo);
- Serious heart condition, peripheral vascular disease, coronary artery disease (myocardial infarction<6 mo), Class III, IV Congestive Heart Failure;
- Severe anemia (Hgb < 8.0 g/dL);
- Liver or renal disease;
- Diabetes;
- Severe osteoarthritis;
- Fracture in upper or lower extremity within the last 6 months;
- Upper or lower extremity amputation;
- Anticoagulant therapy (aspirin use is permitted);
- Parkinson's disease;
- Severe psychiatric disease or psychological disorder (e.g., severe depression, bi-polar disorder, schizophrenia) or current use of antipsychotics;
- Current use of anabolic medications (e.g., growth hormone or testosterone) or anticholinesterase inhibitor (i.e., Aricept);
- High amounts of physical activity (i.e., running, bicycling, etc.) > 120 min/week;
- Excessive alcohol use (>2 drinks per day);
- Use of tobacco products;
- Resting heart rate > 120 bpm;
- Blood pressure with Systolic > 160mmHg and Diastolic >90mmHg;
- History of significant head injury leading to cognitive impairments;
- Visual or hearing impairments that would interfere with testing;
- Current consumption of any dietary supplements containing resveratrol, quercetin, or P. cuspidatum, grape seed extract, or ginko biloba;
- Allergies to papaya or foods with similar compounds (i.e., banana, avocado, kiwi, chestnuts, hazel nuts)
- Allergy to latex;
- Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment;
- Center for Epidemiological Studies - Depression Scale (CES-D) Score > 20.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fermented Papaya Preparation (FPP)
A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks.
Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner.
Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
|
A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks.
Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner.
Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
Other Names:
A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks.
Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner.
Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
|
Placebo Comparator: Sugar Pill
A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks.
Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner.
Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
|
A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks.
Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner.
Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
Other Names:
A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks.
Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner.
Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interleukin-6 (IL-6) will be tested at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
Blood test performed.
|
Change from 8 weeks and 20 weeks
|
Tumor necrosis factor-α (TNF-α) will be tested at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
Blood test will be performed.
|
Change from 8 weeks and 20 weeks
|
C - reactive protein (CRP) will be tested at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
Blood test will be performed.
|
Change from 8 weeks and 20 weeks
|
Myeloperoxidase (MPO) will be tested at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
Blood test will be performed.
|
Change from 8 weeks and 20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short Physical Performance Battery
Time Frame: Change from 8 weeks and 20 weeks
|
Physical function test to assess functional performance on different tasks including timed short distance walk, repeated chair stands, and a balance test.
|
Change from 8 weeks and 20 weeks
|
6 Minute Walk Test performed at weeks 8 and 20.
Time Frame: Change from 8 weeks and 20 weeks
|
The 6 Minute Walk tests functional walking endurance.
Participants will be asked to walk at a comfortable pace for 6 minutes.
Total distance completed, blood pressure, and pulse rate will be measured.
|
Change from 8 weeks and 20 weeks
|
Health-related quality of life performed at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
RAND SF-36 Short Form Health Survey (SF-36) measures eight domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, vitality (energy/fatigue), emotional well being, bodily pain, social functioning, and general health perceptions.
|
Change from 8 weeks and 20 weeks
|
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) performed at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
FACIT-Fatigue is a measure of physical and functional consequences of fatigue, with lower scores indicating more fatigue.
|
Change from 8 weeks and 20 weeks
|
Brief Fatigue Symptom Inventory (FSI)
Time Frame: Change from 8 weeks and 20 weeks
|
FSI is a measure of physical and functional consequences of fatigue.
|
Change from 8 weeks and 20 weeks
|
Superoxide dismutases (SOD) tested at weeks 8 and 20.
Time Frame: Change from 8 weeks and 20 weeks
|
Blood test will be performed.
|
Change from 8 weeks and 20 weeks
|
Glutathione Peroxidase tested at weeks 8 and 20.
Time Frame: Change from 8 weeks and 20 weeks
|
Blood test will be performed.
|
Change from 8 weeks and 20 weeks
|
Total Antioxidant Capacity will be tested at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
Blood test will be performed.
|
Change from 8 weeks and 20 weeks
|
Muscle tissue oxygenation tested at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
Participants will be asked to perform a leg extension endurance exercise with electrodes placed on their forehead and thigh.
|
Change from 8 weeks and 20 weeks
|
Brain tissue oxygenation tested at weeks 8 and 20
Time Frame: Change from 8 weeks and 20 weeks
|
Participants will complete a series of memory and thinking tasks while wearing electrodes on their head.
The N-Back Test that measures working memory will be conducted for 10 minutes.
|
Change from 8 weeks and 20 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen D Anton, PhD, University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB20140628
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom
-
Amazentis SAproDERM GmbHCompleted
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
Clinical Trials on Fermented Papaya Preparation (FPP)
-
Ohio State UniversityOsato Research InstituteCompleted
-
Wolfson Medical CenterUnknown
-
Indiana UniversityOsato Research InstituteCompletedHealing Wound | Diabetic Wound | Supplements | FPP | Fermented Papaya PreparationUnited States
-
University of FloridaOsato Research InstituteCompleted
-
Ohio State UniversityOsato Research InstituteCompletedWound | Negative Pressure Therapy | Open Wound | Type II Obese Diabetic | Type II Non-Obese DiabeticUnited States
-
Hadassah Medical OrganizationUnknownAnemia | Chronic Kidney Disease Stage 5